PharVision Advisers’s Protolabs PRLB Stock Holding History

PharVision Advisers’s Portfolio PRLB Stock Details PRLB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-6,582	Closed	-$257K	–	470
2024 Q4	$257K	Buy	+6,582	New	+$237K	0.22%	210

Other funds holding PRLB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PharVision Advisers's PRLB Position: Q1 2025 in Review

PharVision Advisers sold out of Protolabs (PRLB) in Q1 2025, closing a stake of 6,582 shares — an estimated $257K sold.

PharVision Advisers first reported a position in PRLB in Q4 2024 and held it in 1 quarter. The position peaked at $257K in Q4 2024. 188 funds tracked by Wall St. Rank hold PRLB as of Q1 2025.

PharVision Advisers reported no remaining Protolabs position as of Q1 2025 after selling out during the quarter.
PharVision Advisers sold 6,582 Protolabs shares in Q1 2025, an estimated $257K.
PharVision Advisers first reported a position in Protolabs in Q4 2024 and held it in 1 quarter.
PharVision Advisers's Protolabs position peaked at $257K in Q4 2024.
188 funds tracked by Wall St. Rank held Protolabs as of Q1 2025.

Based on PharVision Advisers's 13F filing for Q1 2025, filed 15 May 2025.